NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd executive Fong Hei Yue Tina, who serves as Chief Marketing Officer and director, has filed a Form 3 reporting beneficial ownership of 39 Class B Ordinary Shares. This filing reflects an initial statement of holdings, with no buy or sell transactions indicated in the data.
NewGenIvf Group Ltd director files initial ownership report. Director Ching Chan Florianna Ann Chi Wan submitted a Form 3 as an insider of NewGenIvf Group Ltd. The filing reports no insider transactions, exercises, gifts, or restructurings and serves only as an initial statement of beneficial ownership.
NewGenIvf Group Ltd director Tam Chun Wa submitted an initial ownership report on Form 3. The filing lists Tam Chun Wa as a director of the company but does not report any share purchases, sales, or other insider transactions.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Limited registers the resale of up to 100,000,000 Class A Ordinary Shares to satisfy registration rights held by certain selling securityholders, including shares issuable to White Lion Capital and JAK Opportunities VI LLC pursuant to various note conversions and warrant exercises.
The prospectus states the company is not selling any shares here and will not receive resale proceeds; however, NewGenIvf may receive up to $500,000,000 from sales to White Lion under the White Lion Purchase Agreement, subject to conditions. The prospectus lists selling methods and distributions including brokerage, block trades, and underwritten offerings.
Key context: last reported close was $0.50 (reported March 12, 2026), outstanding shares were 2,273,790 Class A and 275 Class B as of March 12, 2026, and the company regained Nasdaq minimum bid-price compliance after reverse stock splits and received transfer approval to the Nasdaq Capital Market on February 27, 2025.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.